Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
Rhea-AI Summary
Cabaletta Bio (Nasdaq: CABA) priced an underwritten public offering of 51,725,000 shares of common stock at $2.90 per share, producing approximately $150 million in gross proceeds. The offering is expected to close on or about May 5, 2026 and included participation from Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management and Eli Lilly.
The shares are being sold by Cabaletta under an effective Form S-3-ASR registration and are subject to customary closing conditions.
Positive
- Gross proceeds of approximately $150 million
- 51,725,000 new shares issued to raise operating capital
- Participation from strategic and institutional investors including Eli Lilly
Negative
- Issuance of 51,725,000 shares will dilute existing shareholders
- Offering price of $2.90 may put short-term pressure on the market price
News Market Reaction – CABA
In the May 4 session, CABA gained 30.27%, reflecting a significant positive market reaction. Argus tracked a peak move of +35.9% during that session. Our momentum scanner triggered 76 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 12.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Equity offering priced | Negative | -25.5% | Pricing of public offering of common stock and warrants targeting gross proceeds. |
| Jun 11 | Equity offering proposed | Negative | -25.5% | Announcement of proposed public offering of common stock and warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior offerings in June 2025 were followed by sharp negative reactions around -25.53%, suggesting equity raises have historically pressured the stock.
Over the past year, Cabaletta has used public offerings to fund development of its autoimmune-focused cell therapy pipeline. In June 2025, the company announced and then priced a public offering of common stock and warrants, seeking about $100M in gross proceeds. Those events, both tagged as offerings, each saw a -25.53% price reaction over 24 hours. Today’s underwritten common stock offering fits this established pattern of capital raising via equity markets.
Key Terms
underwritten offering financial
at-the-market price financial
shelf registration statement regulatory
Form S-3-ASR regulatory
prospectus supplement regulatory
book-running managers financial
lead manager financial
Nasdaq rules regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately
The purchase price for the common stock is
TD Cowen, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.
The shares of common stock are being offered by Cabaletta pursuant to a shelf registration statement on Form S-3-ASR (File No. 333-278126), as amended by that certain Post-Effective Amendment No. 1 to Form S-3 (No. 333-278126) and that certain Post-Effective Amendment No. 2 to Form S-3 (No. 333-278126), which was declared effective by the U.S. Securities and Exchange Commission (SEC) on March 31, 2025. The prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus may also be obtained, when available, by contacting: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, by mail at Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor Fitzgerald & Co. by mail at Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York 10022 or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Forward-Looking Statements
This press release contains “forward-looking statements” of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: the satisfaction of customary closing conditions related to the offering and sale of securities; the Company’s ability to complete the offering; and use of capital, expenses, future accumulated deficit and other financial results in the future.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to completion of the public offering on the anticipated terms, or at all, include, but are not limited to, market conditions and the satisfaction of customary closing conditions related to the public offering. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Cabaletta’s most recent annual report on Form 10-K filed on March 23, 2026 and our subsequent quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta’s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement related to the public offering to be filed with the SEC.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
